For additional information about our clinical trials, please contact us at firstname.lastname@example.org.
Study examining the safety and tolerability of a single dose of VY-AADC01 in patients with advanced Parkinson’s Disease.
Active, not recruiting. Enrolled patients between the ages of 40-70 who have been diagnosed with Parkinson’s disease for at least five years, have several hours of “off time” each day and have varying responses to their current medication.
A Phase 1b open-label study to include up to 20 patients with advanced Parkinson’s disease and disabling motor fluctuations, treated with a single administration of VY-AADC01. The study will evaluate the safety and tolerability of ascending dose levels of VY-AADC01 delivered into the brain.
For more information, please visit www.clinicaltrials.gov.